Clinical results of and prospects for the use of controlled-release antiepileptic drugs: a new once-daily levetiracetam formulation
Many antiepileptic drugs (AEDs) have a short half-life (T1/2) with a wide fluctuation from peak to trough blood concentrations. According to this pharmacokinetic profile, there may be both adverse events (AEs) due to the increase in a blood drug concentrations and seizures as a result of its fall, w...
Main Author: | P. N. Vlasov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2017-11-01
|
Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
Subjects: | |
Online Access: | https://nnp.ima-press.net/nnp/article/view/780 |
Similar Items
-
Levetiracetam effectiveness as add-on therapy in Bulgarian patients with drug-resistant epilepsy
by: Ekaterina I. Viteva, et al.
Published: (2021-04-01) -
Pharmacokinetics of levetiracetam in neonates with seizures
by: Merhar, Stephanie L., M.D.
Published: (2011) -
Levetiracetam – epilepsy treatment, pharmacokinetics, mechanism of action, interaction and toxicity
by: Piotr Kozłowski, et al.
Published: (2015-04-01) -
Levetiracetam Therapeutic Drug Monitoring in a Large Cohort of Korean Epileptic Patients
by: Changhee Ha, et al.
Published: (2021-08-01) -
Once-Daily Extended-Release Levetiracetam Improves Medication Compliance in Adolescent Epilepsy Patients
by: Seung Yeon Jung, et al.
Published: (2021-04-01)